Detalles de la búsqueda
1.
Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy.
Blood
; 141(6): 609-619, 2023 02 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36351239
2.
Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy.
Blood
; 139(14): 2173-2185, 2022 04 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34871373
3.
Electronic symptom monitoring in pediatric patients hospitalized for chemotherapy.
Cancer
; 127(16): 2980-2989, 2021 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33945640
4.
Medication contaminants as a potential cause of anaphylaxis to vincristine.
Pediatr Blood Cancer
; 65(1)2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-28834048
5.
Capturing the young child's reports of cancer treatment tolerability: Does our practice reflect an assumption that they cannot report?
Pediatr Blood Cancer
; 70(1): e30028, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36250991
6.
Commentary on King-Kallimanis et al.: Inadequate measurement of symptomatic adverse events in immunotherapy registration trials.
Clin Trials
; 16(3): 327-328, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30895807
7.
INSPIRED Symposium Part 4A: Access to CAR T Cell Therapy in Unique Populations with B Cell Acute Lymphoblastic Leukemia.
Transplant Cell Ther
; 30(1): 56-70, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37821078
8.
Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia.
Blood Adv
; 8(9): 2182-2192, 2024 May 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38386999
9.
Reply to: Medication contaminants as a potential cause of anaphylaxis to vincristine: What about drug specific antigens?
Pediatr Blood Cancer
; 65(2)2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29049863
10.
Unrelated donor α/ß T cell- and B cell-depleted HSCT for the treatment of pediatric acute leukemia.
Blood Adv
; 6(4): 1175-1185, 2022 02 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-34872106
11.
Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19.
Clin Cancer Res
; 28(17): 3804-3813, 2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35705524
12.
CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
Lancet Haematol
; 8(10): e711-e722, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34560014
13.
Use of Patient-Reported Outcomes to Understand & Measure the Patient Experience of Novel Cell and Gene Therapies.
Ther Innov Regul Sci
; 54(6): 1566-1575, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32572771
14.
Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group.
J Clin Oncol
; 37(1): 12-21, 2019 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30379624
15.
Symptom Monitoring in Pediatric Oncology Using Patient-Reported Outcomes: Why, How, and Where Next.
Patient
; 11(2): 147-153, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29071524
16.
Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia.
Expert Rev Anticancer Ther
; 18(10): 959-971, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30111196
17.
Patient-Reported Outcomes in Pediatric Oncology: The Patient Voice as a Gold Standard.
JAMA Pediatr
; 174(11): e202868, 2020 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32832974
18.
Reporting Standards for Patient-Reported Outcomes in Clinical Trial Protocols and Publications.
J Natl Cancer Inst
; 111(11): 1116-1117, 2019 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30959517
Resultados
1 -
18
de 18
1
Próxima >
>>